Emendo Biotherapeutics scores $61 mln Series B

Emendo Biotherapeutics, a provider of synthetic biology to address untreatable diseases, has raised $61 million in Series B funding.

Emendo Biotherapeutics, a provider of synthetic biology to address untreatable diseases, has raised $61 million in Series B funding. AnGes Inc led the round.

Source: Press Release